<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285086</url>
  </required_header>
  <id_info>
    <org_study_id>P1101 ET</org_study_id>
    <nct_id>NCT04285086</nct_id>
  </id_info>
  <brief_title>Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance</brief_title>
  <acronym>SURPASS ET</acronym>
  <official_title>A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EPS International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brightech International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PharmaEssentia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to&#xD;
      compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months&#xD;
      of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed&#xD;
      response to HU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PharmaEssentia Corporation is developing a pegylated (PEG) IFN-α product, P1101, for the&#xD;
      treatment of ET.&#xD;
&#xD;
      Available clinical data and experience with P1101 in PV shows that the compound, with proper&#xD;
      dose modifications, is effective in controlling disease in a significant proportion of&#xD;
      subjects with ET. Further, its increased serum half-life presents distinct advantages for ET&#xD;
      treatment over that of standard IFN-α and other available PEG IFN-α therapy. This pivotal&#xD;
      Phase 3 study will establish the efficacy and safety of P1101 in ET subjects.&#xD;
&#xD;
      The enrolled subjects will be randomized into two arms, the test arm is P1101, the control&#xD;
      arm is ANA. The overall duration for each eligible patient is 14 months, including screening&#xD;
      (1 month), treatment (12 months) and follow-up (1 month) period. Efficacy evaluations, safety&#xD;
      assessments, and PK and immunogenicity evaluations of P1101 will be performed.&#xD;
&#xD;
      Evaluation of efficacy will include clinical laboratory assessments, allelic burden&#xD;
      measurements of CALR, JAK-2, and MPL, spleen size measurements, bone marrow sampling,&#xD;
      EQ-5D-3L, and MPN-SAF TSS completion.&#xD;
&#xD;
      Evaluation of safety will include assessing vital signs, clinical safety laboratory tests,&#xD;
      physical examinations, ECG evaluation, heart ECHO, lung X-ray, ECOG performance status,&#xD;
      ocular examination, and AEs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental Drug (Biological): Ropeginterferon alfa-2b (P1101), Q2W, SC injection Control Drug: Anagrelide, capsules, daily, p.o.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral blood count remission</measure>
    <time_frame>month 9 and month 12</time_frame>
    <description>platelets ≤400 x 109/L AND white blood cells (WBC) &lt;9.5 x 109/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement or non-progression in disease-related signs</measure>
    <time_frame>month 9 and month 12</time_frame>
    <description>splenomegaly</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Large symptoms improvement or maintain non-progression</measure>
    <time_frame>month 9 and month 12</time_frame>
    <description>based on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of hemorrhagic or thrombotic events</measure>
    <time_frame>month 9 and month 12</time_frame>
    <description>absence of hemorrhagic or thrombotic events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durable response</measure>
    <time_frame>month 3 and month 6</time_frame>
    <description>measure durable response at month 3 and 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal rate</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure longitudinal rate of change in the ELN response rates over the 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>measure response rate based on peripheral blood count remission, no signs of progressive disease, and absence of any hemorrhagic or thrombotic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of thromboembolic events</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure occurrence of thromboembolic events over the 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first peripheral blood count remission response</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure time to first peripheral blood count remission response over the 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of peripheral blood count remission response</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure duration of peripheral blood count remission response over the 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement assessed by the EuroQOL 5 dimensions 3 level version (EQ-5D-3L) questionnaire</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure symptomatic improvement assessed by the EuroQOL 5 dimensions 3 level version (EQ-5D-3L) questionnaire over the 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement assessed by the 10-item MPN-SAF TSS</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure symptomatic improvement assessed by the 10-item MPN-SAF TSS over the 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CALR, MPL, and JAK-2 allelic burden over time</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure change of CALR, MPL, and JAK-2 allelic burden over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement or non-progression of spleen size assessment</measure>
    <time_frame>over the 12 months</time_frame>
    <description>measure spleen size over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone marrow histological remission</measure>
    <time_frame>over the 12 months</time_frame>
    <description>the disappearance of megakaryocyte hyperplasia and absence of &gt;grade 1 reticulin fibrosis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>Ropeginterferon alfa-2b (P1101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-filled Syringe, Q2W, SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anagrelide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsules, Daily, p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ropeginterferon alfa-2b</intervention_name>
    <description>Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement</description>
    <arm_group_label>Anagrelide</arm_group_label>
    <arm_group_label>Ropeginterferon alfa-2b (P1101)</arm_group_label>
    <other_name>Anagrelide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥18 years old&#xD;
&#xD;
          2. Subjects diagnosed with high-risk ET (either older than 60 years and JAK2V617-positive&#xD;
             at screening, or having disease-related thrombosis or hemorrhage in the past),&#xD;
             diagnosed according to the World Health Organization (WHO) 2016 criteria&#xD;
&#xD;
          3. Subjects have received prior HU for ET, while the washout between the last dose of HU&#xD;
             and randomization should not be shorter than 14 days&#xD;
&#xD;
          4. Interferon treatment-naïve, or anti-P1101 binding antibody negative at screening and&#xD;
             the washout between last dose of interferon and randomization should not be shorter&#xD;
             than 14 days.&#xD;
&#xD;
          5. Documented resistance/intolerance to prior HU for ET, referencing modified ELN&#xD;
             criteria (Barosi, et al, 2007), whereby at least one of the following criteria is met:&#xD;
&#xD;
             Platelet count &gt;600 x 109/L at ≥2 g/day (or ≥2.5 g/day if subject body weight &gt;80 kg)&#xD;
             or maximally tolerated dose if &lt;2 g/day after at least 3 months of HU, or Platelet&#xD;
             count &gt;400 x 109/L and WBC count &lt;2.5 x 109/L at any dose and any duration of HU, or&#xD;
             Platelet count &gt;400 x 109/L and hemoglobin (HGB) &lt;10 g/dL at any dose and any duration&#xD;
             of HU, or Presence of HU-related toxicities at any dose and any duration of therapy&#xD;
             (e.g., leg ulcers, mucocutaneous manifestations, pneumonitis, or HU-related fever), or&#xD;
             Platelet count &gt;450 x 109/L at any dose and any duration of HU. The actual dose and&#xD;
             duration of HU must be recorded on the eCRF. Moreover, if patient received one dose of&#xD;
             HU, the reason why subject was judged to be HU resistance/intolerance must be recorded&#xD;
             on the eCRF.&#xD;
&#xD;
          6. Platelets &gt;450 x 109/L at screening&#xD;
&#xD;
          7. WBC &gt;10 x 109/L at screening&#xD;
&#xD;
          8. HGB ≥11 g/dL at screening for males and 10 g/dL at screening for females&#xD;
&#xD;
          9. Neutrophil count ≥1.0 x 109/L at screening&#xD;
&#xD;
         10. Adequate hepatic function defined as bilirubin ≤1.5 x upper limit normal (ULN),&#xD;
             prothrombin time (PT) (international normalized ratio, INR) ≤1.5 x ULN, albumin &gt;3.5&#xD;
             g/dL, alanine aminotransferase ≤2.0 x ULN, aspartate aminotransferase ≤2.0 x ULN at&#xD;
             screening&#xD;
&#xD;
         11. Creatinine clearance ≥40 mL/min (by Cockcroft-Gault equation)&#xD;
&#xD;
         12. Males and females of childbearing potential, as well as all women &lt;2 years after the&#xD;
             onset of menopause, must agree to use an acceptable form of birth control until 28&#xD;
             days following the last dose of the study drug, and females must agree to not&#xD;
             breastfeed during the study&#xD;
&#xD;
         13. Written informed consent obtained from the subject and ability for the subject to&#xD;
             comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any subject requiring a legally authorized representative&#xD;
&#xD;
          2. Any contraindications or hypersensitivity to IFN-α or ANA and their excipients&#xD;
&#xD;
          3. Known risk factors for QT-prolongation (e.g., congenital long QT, known history of&#xD;
             acquired QT-prolongations). Medications that can prolong QTc and induce hypokalemia&#xD;
             will not be allowed in the study.&#xD;
&#xD;
          4. Co-morbidity with severe or serious condition that, in the Investigator's opinion,&#xD;
             would jeopardize the safety of the subject or their compliance with the protocol,&#xD;
             including significant cardiac disease (including New York Heart Association Class&#xD;
             III-IV congestive heart failure and clinically significant arrhythmias) and pulmonary&#xD;
             hypertension&#xD;
&#xD;
          5. History of major organ transplantation&#xD;
&#xD;
          6. Pregnant or lactating females&#xD;
&#xD;
          7. Subjects with any other significant medical conditions that, in the opinion of the&#xD;
             Investigator, would compromise the results of the study or may impair compliance with&#xD;
             the requirements of the protocol, including but not limited to:&#xD;
&#xD;
               1. Documented autoimmune disease at screening or in the history (e.g., thyroid&#xD;
                  dysfunction, hepatitis, idiopathic thrombocytopenic purpura, scleroderma,&#xD;
                  psoriasis, or any arthritis of autoimmune origin)&#xD;
&#xD;
               2. Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at&#xD;
                  screening that, in the Investigator's opinion, would jeopardize the safety of the&#xD;
                  subject or their compliance with the protocol&#xD;
&#xD;
               3. Infections with systemic manifestations (e.g., bacterial, fungal, or human&#xD;
                  immunodeficiency virus [HIV], except hepatitis B [HBV] and/or hepatitis C [HCV],&#xD;
                  at screening)&#xD;
&#xD;
               4. Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular&#xD;
                  degeneration) or clinically relevant ophthalmological disorder (due to diabetes&#xD;
                  mellitus or hypertension)&#xD;
&#xD;
               5. History or presence of clinically relevant depression, or previous suicide&#xD;
                  attempts or at any risk of suicide at screening, in the judgement of the&#xD;
                  Investigator&#xD;
&#xD;
               6. History or presence of clinically significant neurodegenerative diseases&#xD;
&#xD;
               7. History of any malignancy within 5 years (except Stage 0 chronic lymphocytic&#xD;
                  leukemia, basal cell, squamous cell, and superficial melanoma)&#xD;
&#xD;
               8. History of alcohol or drug abuse within the last year&#xD;
&#xD;
               9. History or evidence of any other MPN&#xD;
&#xD;
          8. Use of any investigational drug &lt;4 weeks prior to the first dose of study drug or not&#xD;
             recovered from effects of prior administration of any investigational agent&#xD;
&#xD;
          9. Subjects with documented ANA resistance or intolerance (see Appendix 8 for&#xD;
             definition).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiaki Sato, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>PharmaEssentia Japan K.K.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Zimmerman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PharmaEssentia USA Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshiaki Sato, MD/PhD</last_name>
    <phone>+81 3 68669531</phone>
    <email>toshiaki_sato@pharmaessentia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TingFang Wang, MS/MHA</last_name>
    <phone>+886 2 26557688</phone>
    <phone_ext>7890</phone_ext>
    <email>tingfang_wang@pharmaessentia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Anderson</last_name>
      <email>anderson.crystal2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Palmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Al Douri</last_name>
      <email>aaldouri@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Abdulraheem Yacoub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Division of Oncology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Gordon</last_name>
      <email>kdgordon@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lonette Sandy</last_name>
      <email>lonette.sandy@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>John Mascarenhas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Lam</last_name>
      <email>aml7017@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Ghaith Abu-Zeinah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichole Ard</last_name>
      <email>nard@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Srdan Verstovsek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Rodriguez</last_name>
      <email>RodriguezT1@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Ruben Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pena</last_name>
      <email>karen.pena@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Tashi Tsewang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Jacobs</last_name>
      <email>pjacobs@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Michaelis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NanFang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technolog</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai Jiao Tong University school of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0204</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0329</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki City</city>
        <state>Miyazaki</state>
        <zip>889-1692</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Shizuoka Hospital</name>
      <address>
        <city>Izunokuni</city>
        <state>Shizuoka</state>
        <zip>410-2295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo City</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Bunkyo City</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa City</city>
        <state>Tokyo</state>
        <zip>141-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku City</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Yamanashi</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiayi Chang Gung Memorial Hospital</name>
      <address>
        <city>Chiayi</city>
        <zip>61363</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential Thrombocythemia</keyword>
  <keyword>Ropeginterferon</keyword>
  <keyword>P1101</keyword>
  <keyword>PharmaEssentia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

